Methyljasmonate Displays In Vitro and In Vivo Activity against Multiple Myeloma Cells

Por Klippel, Steffen, Jakubikova, Jana, Delmore, Jake, Ooi, Melissa, McMillin, Douglas, Kastritis, Efstathios, Laubach, Jacob, Richardson, Paul G., Anderson, Kenneth C., Mitsiades, Constantine S.
Publicado no Br J Haematol (2012)

Emerging treatments of multiple myeloma; beyond IMIDs and bortezomib

Por Mitsiades, Constantine S., Hideshima, Teru, Chauhan, Dharminder, McMillin, Douglas W., Klippel, Steffen, Laubach, Jacob P., Munshi, Nikhil C., Anderson, Kenneth C., Richardson, Paul G.
Publicado em 2009

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

Por O’Connor, Robert, Ooi, Melissa G., Meiller, Justine, Jakubikova, Jana, Klippel, Steffen, Delmore, Jake, Richardson, Paul, Anderson, Kenneth, Clynes, Martin, Mitsiades, Constantine S., O’Gorman, Peter
Publicado no Cancer Chemother Pharmacol (2013)

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents

Por Leiba, Merav, Jakubikova, Jana, Klippel, Steffen, Mitsiades, Constantine S., Hideshima, Teru, Tai, Yu-Tzu, Leiba, Adi, Pines, Mark, Richardson, Paul G., Nagler, Arnon, Anderson, Kenneth C.
Publicado no Br J Haematol (2012)

Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation

Por McMillin, Douglas W., Delmore, Jake, Negri, Joseph, Ooi, Melissa, Klippel, Steffen, Miduturu, Chandrasekhar V., Gray, Nathanael S., Richardson, Paul G., Anderson, Kenneth C., Kung, Andrew L., Mitsiades, Constantine S.
Publicado em 2011

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465

Por Negri, Joseph M., McMillin, Douglas W., Delmore, Jake, Mitsiades, Nicholas, Hayden, Patrick, Klippel, Steffen, Hideshima, Teru, Chauhan, Dharminder, Munshi, Nikhil C., Buser, Carolyn A., Pollard, John, Richardson, Paul G., Anderson, Kenneth C., Mitsiades, Constantine S.
Publicado em 2009

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity

Por McMillin, Douglas W., Delmore, Jake, Weisberg, Ellen, Negri, Joseph M., Geer, D. Corey, Klippel, Steffen, Mitsiades, Nicholas, Schlossman, Robert L., Munshi, Nikhil C., Kung, Andrew L., Griffin, James D., Richardson, Paul G., Anderson, Kenneth C., Mitsiades, Constantine S.
Publicado em 2010

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Por Jakubikova, Jana, Adamia, Sophia, Kost-Alimova, Maria, Klippel, Steffen, Cervi, David, Daley, John F., Cholujova, Dana, Kong, Sun-Young, Leiba, Merav, Blotta, Simona, Ooi, Melissa, Delmore, Jake, Laubach, Jacob, Richardson, Paul G., Sedlak, Jan, Anderson, Kenneth C., Mitsiades, Constantine S.
Publicado em 2011

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma

Por Jakubikova, Jana, Cervi, David, Ooi, Melissa, Kim, Kihyun, Nahar, Sabikun, Klippel, Steffen, Cholujova, Dana, Leiba, Merav, Daley, John F., Delmore, Jake, Negri, Joseph, Blotta, Simona, McMillin, Douglas W., Hideshima, Teru, Richardson, Paul G., Sedlak, Jan, Anderson, Kenneth C., Mitsiades, Constantine S.
Publicado em 2011